In summary, our study highlights TDP1 as a potential target for reducing the size of CCTG repeat sequences, offering a new strategy to treat DM2 and possibly applicable to a broad spectrum of repeat expansion diseases. Here, TDP1 is linked to myotonic dystrophy type 2.